{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 3b3c7981-d790-4235-91b1-b1cff933cdab --><h2>Changes</h2><!-- end field 3b3c7981-d790-4235-91b1-b1cff933cdab -->","summary":null,"htmlStringContent":"<!-- begin item 2c32df10-d7f7-4422-8ad6-29846dfa087e --><!-- begin field 0276684e-b7a6-406d-9d85-186adedc8d39 --><p><strong>January 2021 </strong>— minor update. Hypersensitivity reactions added as an adverse effect of propylthiouracil in line with updated manufacturer's SPC.</p><p><strong>August 2020 </strong>— minor update. Broken URL link updated.</p><p><strong>May 2020 </strong>— minor update. Links to British Thyroid Foundation leaflets updated.</p><p><strong>January to February 2020 </strong>— reviewed. A literature search was conducted in December 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. The recommendations have been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Thyroid disease: assessment and management</em> (2019) and other current evidence in the literature. The <em>Diagnosis</em> node in the section on Diagnosis has been expanded to include information on when to suspect Graves' orbitopathy, and the previous node containing this information has been deleted. The <em>Assessment</em> node in the section on Diagnosis has been expanded to include relevant history and examination findings. An additional node on <em>Interpreting thyroid function tests</em> has been added to the section on Diagnosis.</p><!-- end field 0276684e-b7a6-406d-9d85-186adedc8d39 --><!-- end item 2c32df10-d7f7-4422-8ad6-29846dfa087e -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"4f001de0-5ed9-5a56-bc18-04112d3717a4","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field dfc79321-981a-495f-9faa-4a8950b10841 --><h3>Previous changes</h3><!-- end field dfc79321-981a-495f-9faa-4a8950b10841 -->","summary":null,"htmlStringContent":"<!-- begin item f2b4c0d4-0f01-4aa4-ad01-1c48785bcabf --><!-- begin field e74b9614-d39d-4baa-b59b-0d0c24f255a3 --><p><strong>February 2019 </strong>— minor update. Text update to the Prescribing information section to reflect that carbimazole should not be prescribed to women of childbearing age due to increased risk of congenital malformations. Acute pancreatitis has also been added as an infrequent adverse effect.</p><p><strong>April to June 2016 </strong>— reviewed. A literature search was conducted in March 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone minor restructuring. No major changes to the recommendations have been made, but the Prescribing Information section has been expanded.</p><p><strong>January to June 2013 </strong>— reviewed. A literature search was conducted in December 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made. The evidence on antithyroid drug regimens in the treatment of Graves' hyperthyroidism has been updated.</p><p><strong>April 2011 </strong>— topic structure revised to ensure consistency across CKS topics, no changes to clinical recommendations have been made.</p><p><strong>January 2010 </strong>— minor update. Correction of typographical errors in a table. Issued in January 2010.</p><p><strong>December 2007 to March 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This topic incorporates the <em>UK guidelines for the use of thyroid function tests </em>issued by the Association for Clinical Biochemistry, the British Thyroid Association, and the British Thyroid Foundation (2006).</p><p><strong>October 2005 </strong>— minor technical update.</p><p><strong>August 2004 </strong>— reviewed. Validated in November 2004 and issued in February 2005.</p><p><strong>August 2001 </strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>January 1999 </strong>— written. Validated in March 1999 and issued in May 1999.</p><!-- end field e74b9614-d39d-4baa-b59b-0d0c24f255a3 --><!-- end item f2b4c0d4-0f01-4aa4-ad01-1c48785bcabf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}